Dr. Reddy's Laboratories
Other · 12 quarters tracked · source-linked performance and management context.
Latest revenue
₹7,546 Cr
verified financial record
Quarters tracked
12
source records in the directory
Delivery assessment
0
Across 11 tracked commitments: 0 delivered, 11 missed.
Call date
2026-04-??
latest available source date
Signal trajectory
12 actual quartersCurrent read
0/100
Across 11 tracked commitments: 0 delivered, 11 missed.
Latest source read
What changed this quarter?
Dr. Reddy's Q4 FY26 revenue (ex-SSA) was INR 7,969 crore, down 6% YoY, dragged by a INR 453 crore lenalidomide shelf-stock adjustment. EBITDA margin of 19.5% (adjusted) missed the 25% aspirational target, impacted by lower gross margins (48%) and higher SG&A. The base business (ex-lenalidomide) grew double-digits. Management expects FY27 gross margins above 50% and EBITDA margins near 25% as semaglutide launches ramp up. Key risks include delayed semaglutide approvals (Brazil) and competitive pricing erosion in U.S. generics.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Watch
Revenue
₹7,546 Cr
Source date
2026-04-??
Across the record
Quarter history.
History modules